MapLight Therapeutics, Inc. Common Stock (MPLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MapLight Therapeutics, Inc. Common Stock (MPLT) has a cash flow conversion efficiency ratio of -0.129x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-44.87 Million) by net assets ($348.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see MPLT company net worth for the company's overall valuation and market capitalisation.
MapLight Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how MapLight Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
MapLight Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MapLight Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See MapLight Therapeutics, Inc. Common Stock cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Visco Vision Inc.
TW:6782
|
0.061x |
|
Valneva SE
PA:VLA
|
-0.058x |
|
Roma Green Finance Limited Ordinary Shares
NASDAQ:ROMA
|
-0.087x |
|
Holike
SHG:603898
|
-0.001x |
|
Surya Roshni Limited
NSE:SURYAROSNI
|
0.098x |
|
IBEX Ltd
NASDAQ:IBEX
|
0.074x |
|
PostNL NV
AS:PNL
|
0.754x |
|
Concrete Pumping Holdings Class A
NASDAQ:BBCP
|
0.082x |
Annual Cash Flow Conversion Efficiency for MapLight Therapeutics, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of MapLight Therapeutics, Inc. Common Stock from 2022 to 2025. View MapLight Therapeutics, Inc. Common Stock stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $458.37 Million | $-138.14 Million | -0.301x | +55.95% |
| 2024-12-31 | $115.19 Million | $-78.81 Million | -0.684x | +6.22% |
| 2023-12-31 | $71.28 Million | $-52.01 Million | -0.730x | +42.71% |
| 2022-12-31 | $20.87 Million | $-26.58 Million | -1.273x | -- |
About MapLight Therapeutics, Inc. Common Stock
MapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irrit… Read more